Table 2.
Clinical Characteristics of the Localized Prostate Cancer Patient Cohorts
| CHARACTERISTIC | JHH N = 106 |
USE N = 43 |
UW N = 18 |
FHCRC N = 41 |
|---|---|---|---|---|
|
| ||||
| Age median (range) | 62 (43-74) | 63 (41-77) | 60 (50-68) | 63 (43-77) |
|
| ||||
| Gleason Score N (%) | ||||
| 6 | 14 (13%) | 6 (14%) | 2 (11%) | 2 (5%) |
| 3+4 | 51 (48%) | 21 (49%) | 10 (57%) | 23 (56%) |
| 4+3 | 20 (19%) | 5 (11%) | 2 (11%) | 7 (17%) |
| 8-10 | 21 (20%) | 11 (26%) | 4(22%) | 9 (22%) |
|
| ||||
| PSA N (%) | ||||
| <10 | 83 (78%) | 33 (77%) | 15(83%) | 33 (80%) |
| 10-20 | 15 (14%) | 8 (19%) | 3 (17%) | 4 (10%) |
| >20 | 8 (8%) | 2 (4%) | 0 (0%) | 4 (10%) |
|
| ||||
| Pathologic T Stage N (%) | ||||
| pT2 | 64 (60%) | 22 (51%) | 8 (44%) | 26 (64%) |
| pT3a | 30 (29%) | 16 (37%) | 9 (50%) | 10 (24%) |
| pT3b | 12 (11%) | 5 (12%) | 0 (0%) | 5 (12%) |
|
| ||||
| Pathologic N Stage N (%) | ||||
| pNx | 15 (14%) | 7 (16%) | 16(89%) | 34 (83%) |
| pN0 | 86 (81%) | 31 (72%) | 2 (11%) | 5 (12%) |
| pN1 | 5 (5%) | 5 (12%) | 0 (0%) | 2 (5%) |